Kelun-Biotech and Crescent Biopharma forged a collaboration covering SKB105/CR-003 and SKB118, a PD-1 x VEGF bispecific antibody also known as CR-001
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
U.S. and Canada transaction supports continued access to RADICAVA for people living with ALS
Full approval will depend on verification of clinical benefit in a confirmatory trial
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
Subscribe To Our Newsletter & Stay Updated
